Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH001 in Treatment-Resistant Depression
NCT04698603Phase 2Completed
- Sponsor
- GH Research PLC
- Start
- Nov 2019
- Primary completion
- Nov 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of mebufotenin in major depressive disorder (MDD), sponsored by GH Research PLC. Started Nov 2019; status: completed.
02
Drugs
mebufotenin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04698603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04698603.